Showing results (31-40 of 88) with videos related to

Sort By:
Pageof 9
Journal of Acquired Immune Deficiency Syndromes (1999)|July 30, 2021
Poorer Muscle Quality and Quantity With ART Initiation Is Associated With Greater Inflammation and Immune ActivationArianna Kousari, Carlee Moser, Maxine Olefsky, et al.
The Journal of Infectious Diseases|August 31, 2023
ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in OutpatientsJudith S Currier, Carlee Moser, Joseph J Eron, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 29, 2020
Antiretroviral Therapy Initiation Is Associated With Decreased Visceral and Subcutaneous Adipose Tissue Density in People Living With Human Immunodeficiency VirusPaula Debroy, Jordan E Lake, Carlee Moser, et al.
Open Forum Infectious Diseases|October 11, 2021
Advanced Glycation End Products Associated With Cardiometabolic Biomarkers in Treated Human Immunodeficiency Virus InfectionVanessa El Kamari, Katherine Rodriguez, Carlee Moser, et al.
Parkinson'S Disease|April 25, 2012
Postmortem Interval Influences α-Synuclein Expression in Parkinson Disease BrainAlexandra Dumitriu, Carlee Moser, Tiffany C Hadzi, et al.
Antiviral Therapy|September 24, 2016
Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260sTheodoros Kelesidis, Thuy Tien T Tran, Todd T Brown, et al.
The Journal of Infectious Diseases|May 8, 2015
Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or RaltegravirTodd T Brown, Carlee Moser, Judith S Currier, et al.
The Journal of Infectious Diseases|June 30, 2016
Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260sTheodoros Kelesidis, Carlee Moser, James H Stein, et al.
The Journal of Infectious Diseases|August 31, 2023
Validity and Characterization of Time to Symptom Resolution Outcome Measures in the ACTIV-2/A5401 Outpatient COVID-19 Treatment TrialKara W Chew, Carlee Moser, Eunice Yeh, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 2, 2025
Serum Biomarkers in Advanced-Stage AIDS-Associated Kaposi Sarcoma in Resource Limited SettingsMarta Epeldegui, Carlee Moser, Younjung Choi, et al.
Pageof 9